We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
The current 0IHV market cap is 643.21M. The company's latest EPS is USD 0.2066 and P/E is 5.08.
| Year End 31 July 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 110.1M | 76.02M | 117.73M | 107.07M | 31.06M |
| Operating Income | 1.73M | -30.37M | 692k | -15.01M | -24.74M |
| Net Income | 2.49M | -28.52M | 7.88M | -18.26M | 20.29M |
| Year End 31 July 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 106.64M | 112.54M | 113.69M | 95.86M | 121.88M |
| Total Liabilities | 20.61M | 54.16M | 45.11M | 41.4M | 43.42M |
| Total Equity | 86.03M | 58.38M | 68.59M | 54.46M | 78.46M |
| Year End 31 July 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | 4.81M | -17.18M | 387k | -16.59M | -36.98M |
| Investing | -8.13M | -2.17M | -34.5M | 25.22M | 98.98M |
| Financing | 4.19M | 7M | -242k | -241k | -1.13M |
| Market Cap | 643.21M |
| Price to Earnings Ratio | 5.08 |
| Price to Sales Ratio | 3.32 |
| Price to Cash Ratio | 1.25 |
| Price to Book Ratio | 1.31 |
| Dividend Yield | - |
| Shares Outstanding | 98.2M |
| Average Volume (1 week) | 2.5k |
| Average Volume (1 Month) | 1.59k |
| 52 Week Change | 0.00% |
| 52 Week High | 6.55 |
| 52 Week Low | 6.55 |
| Spread (Intraday) | 0 (0%) |
| Company Name | Enzo Biochem Inc |
| Address |
81 executive blvd. ste 3 farmingdale, new york 11735 |
| Website | https://www.enzo.com |
| Industry | medical laboratories (8071) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
